Wound Healing Activity of Aucubin on Hyperglycemic Rat by Kartini, Kartini & Islamie, Ridho
J Young Pharm, 2018; 10(2) Suppl: s136-s139
A multifaceted peer reviewed journal in the field of Pharmacy
www.jyoungpharm.org | www.phcog.net 
Journal of Young Pharmacists, Vol 10, Issue 2 (Suppl), Apr-Jun, 2018 S136
Original Article
INTRODUCTION
Aucubin (Figure 1) is an iridoid glycosides widely distributed in plants 
such as Aucuba japonica, Euphrasia officinalis, Eucommia ulmoides, and 
so on.1 Kartini et al. isolated and evaluated the activity of this compound 
from Plantago major.2 Aucubin activities have been extensively studied, 
such as for anticancer,2-3 immunomodulator,2 and for the treatment of 
mucous membrane inflammation of nasopharyngeal channels.4 In addition, 
aucubin also has wound healing activity on oral mucous and dermal 
wound,5 as well as inhibit the growth of Escherichia coli and Staphylococcus 
aureus.6 However, so far there has been no report on aucubin activity for 
diabetic wound healing.
Diabetic wound differs from wound under normal conditions. High 
blood sugar is a good medium for bacterial growth, and therefore in 
diabetic ulcer patients most likely will have an infection. In addition, 
hyperglycemic patients usually experience ischemia and this condition 
inhibits the wound healing process. Around 6.2% of Indonesian population 
(20-79 years) suffer from diabetes, 8.7% among of them undergo diabetic 
foot ulcers (DFU) and 1.3% to be amputated.7 Diabetic foot ulcer is one 
of the most common chronic complications marked by injury and 
inflammation in the area under the ankle. This wound should be treated 
immediately in order to avoid damage leading to amputation. Wound 
management usually performed for DFU are debridement, maintaining 
wound moisture, controlling inflammation and infection, and epithelial 
edge advancement. One of the most common attempts is to control 
inflammation and infection by using topical antiinflammatory and 
antibacterial.8
It is therefore necessary to perform a further research to evaluate the 
effects of aucubin on the wound healing process under hyperglycemic 
conditions. This study was conducted on hyperglycemic male Wistar rat. 
Aucubin was administered topically on the dorsal portion of the injured 
rat, then the percentage of wound closure and the closing time of the 
wound were observed.
MATERIALS AND METHODS
Materials
Chemicals used in this study were aucubin (Sigma, St. Louis, MO, USA), 
alloxan monohydrate (Sigma, St. Louis, MO, USA), normal saline 
(Otsuka, Indonesia), Ketalar® (Pfizer), Bioplacenton® (Kalbe Farma, 
Indonesia), CMC-Na, glycerine, propilene glycol, demineralised water, 
alcohol, and hair removal cream (Veet®).
Animals
Male Wistar rats (100-200 g) were used in this research. Animals were 
housed under the conditions of room temperature, 70% of relative 
humidity, and a 12-h light-dark cycle. They were supplied with standard 
diet and water ad libitum and acclimatized for two weeks before the 
experiment. All animals were carried out according to the institutional 
rules concerning animal experiments (approval No: 721-KE; Dated 15 
June 2017). 
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ABSTRACT
Objective: Impaired wound healing in diabetic patients is a serious com-
plication leading to amputation and even death. Proper diabetic wound 
management is needed to improve the quality of life of diabetic patients. 
Plantago major (plantain) has been used empirically for wound healing. 
One of its chemical compounds, aucubin, has been studied on non 
hyperglycemic wound. This study was conducted to determine the wound 
healing activity of aucubin on hyperglycemic rats, as a model for diabetic 
wound. Methods: A total of 20 hyperglycemic male rats (Wistar) were 
divided into 4 groups (P1, P2, K1, and K2), and subsequently treated with 
gel of aucubin 20 µg and 40 µg, bioplacenton®, and gel base, respectively. 
The fifth group, P3, was normal rats treated with gel of aucubin 40 µg. 
Drugs were applied topically on animals’ wounds induced on the dorsal 
part (length of 2 cm, a depth of 5 mm), once daily during 21 days. Wound 
healing activity was evaluated based on the percentage of wound closure 
and wound healing time. Results: The results showed that the gel of au-
cubin at the dose of 20 µg and 40 µg could increase the percentage of 
wound closure (100%) compare to the negative control (83%). Moreover, 
gels of aucubin accelerated wound healing time (11.7 days) compared to 
the negative control (24.4 days). Conclusion: Aucubin can be used as a 
drug candidate for diabetic wound healing.
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Figure 1: Chemical structure of aucubin.
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Preparation of aucubin gel 
The dose of aucubin used in this study refered to previous study. Shim 
et al. concluded that the effective dose of aucubin was 50 μl of 0.04% 
and 0.08% solution which were equivalent to 20 µg and 40 μg aucubin, 
respectively.9 In this recent study, aucubin was formulated into gel dosage 
form and administered in 1 FTU (Finger Tip Unit, 0.5 g of gel). One FTU 
of gel contained 20 µg and 40 μg of aucubin, respectively. Composition of 
aucubin gel is presented on Table 1. 
Induction of hyperglycemic
Animals were weighed and their fasting blood glucose levels were deter-
mined using Autocheck® (Germany) before induction. Animals showing 
very low or high glucose levels were replaced. The animals were then 
injected with a single dose of alloxan monohydrate (160 mg/kg BW) in 
normal saline by i.p. route. Control animals (non-hyperglycemic rats) 
were injected with normal saline. Fasting blood glucose level was 
measured two days later to confirm their hyperglycemic status. For blood 
glucose measurement, the blood was drawn from tail vein. Animals are 
considered hyperglycemic if their random blood glucose level reached 
≥ 200 mg/dL. 
Incision wound model 
Animals were anaesthetized with ketamine HCl (Ketalar, 100 mg/kg 
BW, i.p.). Incision wound was induced on the dorsal surface with length 
of ± 2 cm and depth of ± 5 mm using a scalpel. The entire wound was left 
open. Animals were closely observed for any infection and those which 
showed signs of infection were separated, excluded from the study and 
replaced. Animals were then divided into five groups with 5 rats per group, 
as shown on Table 2. All treatments were carried out topically once daily by 
application of 1 FTU (Finger Tip Unit, 0.5 g) of gels on the wound. Wound 
lengths were measured on days of 0, 5, 10, and 21 using digital caliper.
Statistical analysis
Wound healing was evaluated using parameters of the percentage and 
time of wound closure. The length of the wound was measured using 
digital caliper on the day 0, 5, 10, and 21. The percentage of wound 
closure was determined by using the formula: ((L1- L2) / L1) x 100, where 
L1 is the length of wound on the day 0, while L2 is the length of wound 
on the day of observation. Time of healing is the day when the wound 
closes perfectly. All data were then analyzed by one way ANOVA using 
GraphPad Prism statistical software (GraphPad Software Inc., Sandiego, 
California, Windows Version 5.01). Differences were considered statisti-
cally at P < 0.05.
RESULTS 
Effect of aucubin on the wound closure
Effect of aucubin on the wound closure of hyperglycemic rat can be seen 
on Figure 2 and Table 3. The percentage of wound closure of group P1 
and P2 on the day 5 were lower than that of group K2. However, wound 
closure of P2 was higher than K2 on the day 10. The wound closure on 
the day 21 exhibit a significant difference between group K2 with P1, P2, 
P3, and K1.
Effect of aucubin on the wound healing time
Effect of aucubin on the wound healing time of hyperglycemic rat can 
be seen on Table 4. The wound healing time of P2, group treated with 
40 µg aucubin, was significantly shorter than P1 and K1.
DISCUSSION
Various herbs have been studied for their wound healing activity, such 
as: Plantago major, Carica papaya, Malva sylvestris, Terminalia chebula, 
Chrysophyllum cainito, Achyranthes aspera, Azadirachta indica.10-17 
Wound healing is a complex process involving a variety of cellular and 
matrix components acting in concert to reestablish the integrity of the 
injured tissue. The complexity of the healing response can be simplified 
into four broad categories that coincide with the temporal sequence of 
normal healing: hemostasis, inflammation, cell proliferation and tissue 
Tabel 1: Composition of Aucubin Gel.
Ingredient Composition (%)
P1 P 2
Aucubin 0.04 0.08
CMC-Na 4 4
Glycerin 8 8
Propilene glycol 4 4
Demineralised water up to 100 100
Table 2: Grouping and Treatment of Animals.
Group Remarks 
P1 Diabetic experimental rats treated with 20 µg aucubin
P2 Diabetic experimental rats treated with 40 µg aucubin
P3 Normal control rats treated with 40 µg aucubin
K1 Positive control treated with bioplacenton gel
K2 Negative control treated with gel base
Figure 2: Development of wound on hyperglycemic rats treated with aucubin 
gel from day of 0 (a), 5 (b), 10 (c), and 21 (d).
Table 3: Effect of Aucubin on Wound Closure of Hyperglycemic Rats.
Group Wound closure (%)*
Day 5 Day 10 Day 21
P1 18.45 ± 2.19c 58.08 ± 11.59 100.00 ± 0.00
P2 17.86 ± 3.02c 91.86 ± 7.88a 100.00 ± 0.00
P3 31.71 ± 3.62b 94.86 ± 11.49 100.00 ± 0.00
K1 27.28 ± 2.81 44.12 ± 8.78b 100.00 ± 0.00
K2 22.56 ± 4.04a,b,c 44.72 ± 8.79b,c 83.47 ± 7.80a,b,c
*data represent the means ± SD of 5 replications; a = p < 0.05 compared to P1; b = 
p < 0.05 compared to P2; c = p < 0.05 compared to K1.
Table 4: Effect of Aucubin on Wound Healing Time of Hyperglicemic Rats.
Group Wound healing time (day)*
P1 12.80 ± 1.30b,c
P2 10.60 ± 0.55c
P3 10.00 ± 0.70
K1 19.00 ± 1.58
K2 24.40 ± 1.14a,b,c
*data represent the means ± SD of 5 replications; a = p < 0.05 compared to 
P1; b = p < 0.05 compared to P2; c = p<0.05 compared to K1.
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ABBREVIATIONS
DFU: Diabetic Foot Ulcer; CMC-Na: Carboxymethyl cellulose; Ag: An-
tigen; TNF-α: Tumor Necrosis Factor Alpha; IL-6: Interleukin 6; NF-κB: 
Nuclear Factor kappa-light-chain-enhancer of activated B cells; RBL-
2H3: Rat Basophilic Leukemia.
SUMMARY
• Plantago major has been used empirically for wound healing.
• Aucubin, an iridoid glycosides, is widely distributed in plants in-
cluding Plantago major. 
• Topical gel containing aucubin at the dose of 20 µg and 40 µg were 
able to increase the percentage of wound closure and accelerate 
wound healing time on hyperglycemic rat.
• Aucubin can be used as a drug candidate for diabetic wound heal-
ing.
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